Vaxcell Bio Therapeutics
KOSDAQ:323990
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vaxcell Bio Therapeutics
Operating Income
Vaxcell Bio Therapeutics
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics
KOSDAQ:323990
|
Operating Income
-₩15B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Operating Income
₩1.2T
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Operating Income
-₩30B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Operating Income
-₩36.3B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Operating Income
₩106.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
300%
|
CAGR 10-Years
97%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Operating Income
-₩40.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Vaxcell Bio Therapeutics
Glance View
Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. The company is headquartered in Hwasun, Jeollanam-Do and currently employs 47 full-time employees. The company went IPO on 2020-09-22. The firm's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The firm sells its products in domestic and overseas markets.
See Also
What is Vaxcell Bio Therapeutics's Operating Income?
Operating Income
-15B
KRW
Based on the financial report for Dec 31, 2024, Vaxcell Bio Therapeutics's Operating Income amounts to -15B KRW.
What is Vaxcell Bio Therapeutics's Operating Income growth rate?
Operating Income CAGR 5Y
-30%
Over the last year, the Operating Income growth was -31%. The average annual Operating Income growth rates for Vaxcell Bio Therapeutics have been -37% over the past three years , -30% over the past five years .
